Annual Drug Patent Expirations for JUVISYNC
Juvisync is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are four patents protecting this drug and three Paragraph IV challenges.
Drug patent litigation for JUVISYNC.
This drug has seventy patent family members in forty-four countries.
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
